Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
61-75 of 4049 results
Jazz enrolls first patient in JZP-110’s phase 2 trial for excessive sleepiness in PD patients
Jazz Pharmaceuticals has enrolled its first patient for the Phase 2 clinical study of JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, as a potential option for excessive sleepiness (ES) in adult patients with Parkinson's disease.
Contract Research & Services > Clinical Trials > News
Viking's VK2809 demonstrates positive effect in POC study in glycogen storage disease
Preliminary results from a proof-of-concept (POC) study evaluating Viking Therapeutics' VK2809 in an in vivo model of a rare orphan disorder, dubbed glycogen storage disease Ia (GSD 1a), demonstrated an encouraging effect.
Contract Research & Services > Clinical Trials > News
Male contraceptive gel succeds in monkey trials
By PBR Staff Writer
A new type of male contraceptive polymer hydrogel which works by blocking sperm in the vas deferens has been successful in monkey trials.
Contract Research & Services > Clinical Trials > News
GW Pharmaceuticals' Cannabis-derived drug shows promise in brain cancer trial
GW Pharmaceuticals has unveiled positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme, or GBM.
Contract Research & Services > Clinical Trials > News
Immunovaccine’s immuno-oncology candidate to enter phase 2 trial in ovarian cancer
Immunovaccine has announced that the UHN’s Princess Margaret Cancer Centre (PM) will carry out a Phase 2 clinical trial to assess the use of a combination of immunotherapies from Immunovaccine and Merck.
Contract Research & Services > Clinical Trials > News
Ergomed’s insomnia drug meets primary endpoint in phase 2 trial
By PBR Staff Writer
A phase 2 clinical study evaluating Ergomed's Lorediplon met the primary endpoint with high statistical significance, indicating the drug has strong efficacy in sleep maintainance.
Contract Research & Services > Clinical Trials > News
Amgen's Repatha reduces risk of cardiovascular events in FOURIER Outcomes study
Amgen announced that the FOURIER trial assessing whether Repatha (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke).
Contract Research & Services > Clinical Trials > News
Summit outlines phase 3 program for CDI antibiotic ridinilazole
By PBR Staff Writer
Drug discovery and development firm Summit Therapeutics has outlined plans for the design of the phase III programme for its C. difficile treatment, ridinilazole.
Contract Research & Services > Clinical Trials > News
Abeona enrolls first high dose subject in phase 1/2 gene therapy trial for ABO-102
Abeona Therapeutics has enrolled the first high-dose subject in the ongoing Phase 1/2 trial for ABO-102 (AAV-SGSH) in Sanfilippo Syndrome Type A.
Contract Research & Services > Clinical Trials > News
Emergent initiates phase 1b trial to assess broad-spectrum antiviral UV-4B for dengue
Emergent BioSolutions has commenced a Phase 1b multiple ascending dose study to assess the safety and tolerability of its novel antiviral candidate, UV-4B developed as a potential oral treatment for dengue viral infection.
Contract Research & Services > Clinical Trials > News
FDA clears Audentes’ IND application for AT342 to treat Crigler-Najjar syndrome
Audentes Therapeutics’ investigational new drug (IND) application for AT342, its gene therapy product candidate, to treat Crigler-Najjar Syndrome has been cleared by the US Food and Drug Administration (FDA).
Contract Research & Services > Clinical Trials > News
Motif Bio reaches milestone in antibiotic trial
Motif Bio announced that the last patient has finished the treatment phase in REVIVE-1, the Phase 3 clinical trial investigating the safety and efficacy of iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).
Contract Research & Services > Clinical Trials > News
EyeGate’s ocular bandage gel demonstrates positive effect in pilot trial
By PBR Staff Writer
The first-in-human pilot study evaluating EyeGate Pharmaceuticals’ EyeGate Ocular Bandage Gel (OBG) has yielded positive results.
Contract Research & Services > Clinical Trials > News
Kainos Medicine starts phase 1 trials of Parkinson's Disease drug candidate
Kainos Medicine has started phase 1 clinical trials of its Parkinson's Disease drug candidate code-named KM-819.
Contract Research & Services > Clinical Trials > News
Aurinia selects Worldwide Clinical Trials as CRO for phase 3 lupus nephritis study
Worldwide Clinical Trials has been selected as Aurinia Pharmaceuticals' clinical research organization (CRO) for the AURORA phase 3 study of volcosporin to treat active lupus nephritis (LN).
Contract Research & Services > Clinical Trials > News
61-75 of 4049 results